Inari Soininen

Inari Soininen

Auto-generated profile, based on publicly available information

Inari Soininen

Synapse Research Management Partners SL, Madrid, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2023 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
MCMark Cronin
Mark Cronin
SBSamuel J. Belfield
Samuel J. Belfield
KBKatharine A. Briggs
Katharine A. Briggs
SESteven J. Enoch
Steven J. Enoch
JFJames W. Firman
James W. Firman
DSDespoina Sousoni
Despoina Sousoni
In silico predictive models for toxicology include quantitative structure-activity relationship (QSAR) and physiologically based kinetic (PBK) approaches to predict physico-chemical and ADME properties, toxicological effects and internal exposure. Such models are used to fill data gaps as part of chemical risk assessment. There is a growing need to ensure in silico predictive models for toxicology are available for use and that they are reproducible. This paper describes how the FAIR (Findable, Accessible, Interoperable, Reusable) principles, developed for data sharing, have been applied to in silico predictive models. In particular, this investigation has focussed on how the FAIR principles could be applied to improved regulatory acceptance of predictions from such models. Eighteen principles have been developed that cover all aspects of FAIR. It is intended that FAIRification of in silico predictive models for toxicology will increase their use and acceptance.

12 December 2024 in Toxicologic Pathology
Verified
Journal Article
Closed access
TSThomas Steger-Hartmann
Thomas Steger-Hartmann
FSFerran Sanz
Ferran Sanz
FBFrank Bringezu
Frank Bringezu
ISInari Soininen
Inari Soininen
The virtual control group (VCG) concept was originally developed in the IMI2 project eTRANSAFE, using data of control animals which pharmaceutical companies have accrued over decades from animal toxicity studies. This control data could be repurposed to create virtual control animals to reduce or replace concurrent controls in animal studies. Initial work demonstrated the general feasibility of the VCG concept, but implementation requires significant further collaborative efforts. The new Innovative Health Initiative (IHI) project VICT3R aims to address these challenges and to obtain regulatory acceptance for the VCG concept. To achieve these goals, VICT3R will build a database comprising high-quality, standardized, and duly annotated control animal data from past and forthcoming toxicity studies. The VICT3R project will create workflows and computational tools to generate adequate VCGs based on statistical and artificial intelligence (AI) approaches. The validity, reproducibility, and robustness of the resulting VCGs will be assessed by comparing the performance of their use with that of real control groups.

27 October 2025 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
CGChristopher E. Goldring
Christopher E. Goldring
GRGiusy Russomanno
Giusy Russomanno
CPCarmen Pin
Carmen Pin
PTPanuwat Trairatphisan
Panuwat Trairatphisan
KBKylie A. Beattie
Kylie A. Beattie
LLLoic Laplanche
Loic Laplanche

22 October 2025 in NAM Journal
Verified
Journal Article
Open access
FSFerran Sanz
Ferran Sanz
JMJulia Matyjasiak
Julia Matyjasiak
JOJavier Orihuel
Javier Orihuel
CPColleen M. Pike
Colleen M. Pike
ISInari Soininen
Inari Soininen
TSThomas Steger-Hartmann
Thomas Steger-Hartmann
• Transitional strategies based on animal reduction pave the way for the phasing out of animal testing. • Transition from concurrent to virtual control groups in animal studies significantly reduces the number of animals. • Virtual control groups can be generated based on accumulated and curated historical data.